Cholangiocarcinoma 2026: status quo, unmet needs and prioritiesJesús M. Bañales, Apinya Jusakul, Pedro M. Rodrigues et al.|Nature Reviews Gastroenterology & Hepatology|2025Cited by 52
A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancerJames J. Harding, Heung-Moon Chang, Lequn Bao et al.|Future Oncology|2024Cited by 4
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analysesYounghun Han, Rory L. Smoot, Jinyoung Byun et al.|Hepatology|2026Cited by 1